The Raj laboratory has developed significant expertise in:

  • Deceiphering mechanisms of resistance to therapy: understanding why and how drugs or radiation fail is critical to developing novel approaches to targeting therapy resistance.
  • Evaluating protein-protein interactions
    • We have experience using co-immunoprecipitations, proximity ligation assays and in vivo complementation assays for individual interactions
    • We have experience with IP-MS and RIME for global interactions
  • Targeting protein-protein interactions.
    • With Jung-Mo Ahn, Ph.D., of UT Dallas, we have created a new class of drugs known as peptidomimetics.
    • Some of these drugs have actvity in therapy-resistant prostate and breast cancers
    • these drugs are being translated to clinical trials
  • Evaluating ex vivo cultures of prostate cancer.
    • The Raj laboratory has the largest experience in the world in growing cancer tissues from primary and metastatic sites in explant cultures.
    • We have developed Patient derived explants (PDEx), patient derived xenograft explants (PDXEx) and xenograft derived explants (XDEx). 
  • Animal and cellular models of prostate and breast cancer.
    • We have developed multiple models, including several unique to the laboratory.